Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Carboplatin, and Sorafenib in Advanced Bladder Carcinoma
NCT00461851Phase 2Completed
- Sponsor
- Yale University
- Start
- Mar 2007
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in bladder carcinoma, sponsored by Yale University. Primary endpoint: Progression Free Survival. Started Mar 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT00461851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461851.